Although GLP-1 RAs are effective for the treatment of obesity and related comorbid conditions, such as diabetes, the high cost and high rates of gastrointestinal adverse effects can lead to treatment cessation and subsequent weight regain.5 Further data are needed to assess whether trends in metabolic bariatric surgery use will stabilize with ongoing access barriers to GLP-1 RAs. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.